Since its inception in 2001, as a spin-off from German pharma major Bayer, the Italian biotech company has developed a track record as a third party research and discovery services provider for the life science industry.

In addition, Axxam conducts several discovery programs for selected targets which are carried out in partnership with other companies or non-profit organizations.